TIM-3 / HAVCR2 Protein & Antibody

 T cell Immunoglobulin Mucin 3 / Hepatitis A Virus Cellular Receptor 2

TIM-3 / HAVCR2 Products

TIM-3 / HAVCR2 Protein, Recombinant

Molecule	Species	Description	Cat. No
TIM-3/HAVCR2	Human	TIM-3/HAVCR2/Fc Protein, Recombinant	10390-H03H
TIM-3/HAVCR2	Human	TIM-3/HAVCR2/Fc Protein, Recombinant	10390-H08H

TIM-3 / HAVCR2 Antibody

Molecule	Application	Description	Cat. No
Human TIM-3/HAVCR2	WB, ELISA	TIM-3/HAVCR2 Antibody, Mouse MAb	10390-MM04
Human TIM-3/HAVCR2	WB, ELISA	TIM-3/HAVCR2 Antibody, Rabbit MAb	10390-R024
Human TIM-3/HAVCR2	WB, ELISA	TIM-3/HAVCR2 Antibody, Rabbit PAb	10390-RP01
Human TIM-3/HAVCR2	WB, ELISA	TIM-3/HAVCR2 Antibody, Rabbit PAb (Antigen Affinity Purified)	10390-RP02

TIM-3 / HAVCR2 cDNA Clone

Molecule	Species	Description	Cat. No
TIM-3/HAVCR2	Human	Homo sapiens TIM-3/HAVCR2 cDNA Clone(NM_032782.3)	HG10390-M

TIM-3 / HAVCR2 Related Areas

Immunology>>Adaptive Immunity>>T Cell>>Helper T Cell>>TIM-3/HAVCR2

TIM-3 / HAVCR2 Alternative Names

Tim-3, HAVCR2, TIM3, FLJ14428, KIM-3, TIMD3 [Homo sapiens]

TIM-3, HAVCR2, Tim3, RP23-248K2.7, MGC124149, MGC124150, Timd3 [Mus musculus]

TIM-3 / HAVCR2 Background

Hepatitis A virus cellular receptor 2 (HAVCR2), formerly known as T cell immunoglobulin and mucin domain-3 (TIM-3), is a transmembrane glycoprotein expressed on the surface of terminally differentiated Th1 cells but not on Th2 cells. It was the first surface molecule that specifically identifies Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3-Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. It suggests a novel paradigm in which dysregulation of the TIM-3-galectin-9 pathway could underlie chronic autoimmune disease states, such as multiple sclerosis. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear. In tumor rejection model, soluble form of Tim-3 (sTim-3) significantly impaired T cell antitumor immunity, evidenced by decreased antitumor CTL activity and reduced amount of tumor-infiltrating lymphocytes in tumor. sTim-3 as an immunoregulatory molecule that may be involved in the negative regulation of T cell-mediated immune response.

TIM-3 / HAVCR2 Related Studies

1. Geng H, et al. (2006) Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 176(3): 1411-20.
2. Anderson AC, et al. (2006) TIM-3 in autoimmunity. Curr Opin Immunol. 18(6): 665-9.
3. Anderson DE. (2007) TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets. 11(8): 1005-9.
4. Pan HF, et al. (2010) TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep. 37(1): 395-8.